Various clinicopathological parameters, such as histological grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) gene amplification, and American Joint Committee on Cancer (AJCC) stage are currently considered in the prognosis and management of breast cancer [3]. This evidence concerns the gene ERBB2 and breast carcinoma.